TrumpRx to offer discount weight loss drugs after Lilly, Novo deals
The Trump administration made a significant announcement on Thursday regarding a deal to expand access to popular obesity drugs produced by Novo Nordisk and Eli Lilly. This deal aims to provide more coverage for Medicare and Medicaid beneficiaries and lower prices for these drugs.
The administration believes that granting millions more people access to these medications is a crucial step in the fight against chronic diseases. While the exact timeline for the coverage expansion and the specific individuals who will benefit from it are still uncertain, Medicare and Medicaid will receive substantial discounts on the drugs.
Under the terms of the deal, the companies have agreed to sell the treatments for $245 a month across both programs for weight loss and diabetes treatment. Medicare beneficiaries will have a $50 copay, making these drugs more accessible to those who need them.
This initiative is a significant move towards addressing the obesity epidemic and improving the health outcomes of individuals struggling with weight-related issues. By expanding access to these medications and reducing their costs, the administration aims to support overweight and obese individuals in their journey towards better health.
Overall, this deal represents a positive step towards tackling obesity and chronic diseases, and it will be interesting to see how it unfolds in the coming months.
